Skip to main content
. Author manuscript; available in PMC: 2010 May 4.
Published in final edited form as: Int Rev Neurobiol. 2009;84:81–103. doi: 10.1016/S0074-7742(09)00405-X

TABLE I.

Clinical Trials in aMCI

Agent N Duration Endpoint Outcome
Donepezil 269 24 weeks Symptoms Negative
Donepezil/Vitamin E 769 3 years AD Partially positive
Rofecoxib 1200 2–3 years AD Negative
Galantamine 995 2 years CDR 1 Negative
1062 2 years CDR 1 Negative
Rivastigmine 1018 3–4 years AD Negative

AD, Alzheimer’s disease; CDR, clinical dementia rating.